1. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open- label, randomised, crossover study 
Lia Bally, MD, Hood Thabit, PhD, Harald Kojzar, BSc, Julia K Mader, MD, Jehona Qerimi-Hyseni, BSc, Sara Hartnell, BSc, Martin Tauschmann, MD, Janet M Allen, RN, Malgorzata E Wilinska, PhD, Thomas R Pieber, MD, Mark L Evans, MD, Dr Roman Hovorka, PhD 
The Lancet Diabetes & Endocrinology 
Volume 5, Issue 4, Pages (April 2017)
DOI: /S (17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

2. Figure 1
Trial profile
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

3. Figure 2
Median sensor glucose and insulin delivery for the 24 h duration over the study period
Median (IQR) sensor glucose concentration (A) and insulin delivery (B) during closed-loop period (solid red line and red shaded area) and control period (dashed black line and grey shaded area) for the 24 h duration. The horizontal dashed lines show the lower and upper limits of the glucose target range (3·9–10·0 mmol/L).
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

4. Figure 3
Individual values of mean sensor glucose and proportion of time spent with glucose concentration below the target range for the whole study
The size of the circles denotes the proportion of time spent with low glucose (<3·5 mmol/L).
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions